Symbols

LIVN

LivaNova·NASDAQ

--(--)

LIVN fundamentals

LIVN Q4 2025 Earnings

LivaNova (LIVN) released its earnings on Feb 25, 2026: revenue was 360.90M (YoY +12.15%), beat estimates; EPS was 0.86 (YoY +6.17%), beat estimates.

Revenue / YoY

360.90M

+12.15%

EPS / YoY

0.86

+6.17%

Report date

Feb 25, 2026

LIVN Earnings Call Summary for Q4,2025

Strong 2025 Performance: 13% organic revenue growth, 18% operating margin, and $0.86 adjusted EPS.
2026 Outlook: 6.5% revenue growth (6-7% range), 20-21% operating margin, $4.20 EPS midpoint.
Core Growth Drivers: Cardiopulmonary (7-8% growth from HLM upgrades and consumables), Epilepsy (5.5-6.5% from Medicare reimbursement and clinical evidence).
Innovation Investments: $120M capital spend for next-gen oxygenator, OSA device launch in 2027, and digital health platform expansion.
OSA Momentum: PMA expected H1 2026, MRI-compatible device H2 2027, with PolicySync algorithm targeting 50%+ nonresponder conversion.

Earnings

EPS

Revenue

Revenue & Expenses

LIVN has released its 2025 Q4 earnings report, with revenue of 360.92M, reflecting a YoY change of 12.15%, and net profit of 30.91M, showing a YoY change of -44.70%. The Sankey diagram below clearly presents LIVN's revenue sources and cost distribution.

Key Indicators

LivaNova (LIVN) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

LivaNova (LIVN)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

LivaNova (LIVN)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

LivaNova (LIVN)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown